Gallbladder Pain: Drugs That Cause or Treat It

What Gallbladder Pain Actually Feels Like

Biliary colic is a steady, intense ache in the right upper quadrant or epigastrium that typically lasts 30 minutes to 6 hours. It is not the sharp, stabbing sensation many patients expect. The pain often radiates to the right scapula or shoulder, worsens after fatty meals, and may be accompanied by nausea or vomiting. Episodes that persist beyond 6 hours raise concern for acute cholecystitis, which involves gallbladder wall inflammation rather than simple obstruction [1].

The American College of Gastroenterology (ACG) estimates that 10 to 15 percent of U.S. adults have gallstones, but only about 20 percent of stone carriers will ever develop symptoms [2]. This distinction between asymptomatic cholelithiasis and symptomatic disease drives every treatment decision. "Incidentally discovered gallstones in the absence of biliary symptoms should not be treated," the ACG practice guideline states [2]. Prophylactic cholecystectomy carries risk without proven benefit in these patients.

Age, female sex, obesity, rapid weight loss, and certain medications all shift the probability of stones becoming symptomatic. The next sections identify which drugs push patients toward gallstone formation, and which ones clinicians use to manage the pain once it arrives.

Drugs That Can Cause or Worsen Gallbladder Pain

Multiple medication classes alter bile composition, impair gallbladder motility, or both. Recognizing drug-induced cholelithiasis matters because discontinuing the offending agent can prevent recurrence without surgery.

GLP-1 Receptor Agonists

Semaglutide, liraglutide, and tirzepatide slow gastric emptying and reduce gallbladder contractility. In the STEP-1 trial (N=1,961), cholelithiasis occurred in 2.6 percent of subjects receiving semaglutide 2.4 mg versus 1.0 percent on placebo [3]. The SUSTAIN-6 cardiovascular outcomes trial (N=3,297) found a similar signal: gallbladder-related disorders appeared in 1.5 percent of the semaglutide arm compared with 0.4 percent receiving placebo [4]. Rapid weight loss compounds the problem. Each kilogram of fat metabolized releases cholesterol into bile, supersaturating it and promoting crystal nucleation. Patients losing more than 1.5 kg per week on any GLP-1 agonist face the highest risk [5].

Octreotide and Somatostatin Analogues

Octreotide inhibits cholecystokinin release, reducing gallbladder contractility by 40 to 50 percent [6]. Gallstone prevalence reaches 20 to 30 percent within 12 months of continuous octreotide therapy in acromegaly patients, according to data reviewed in the Journal of Clinical Endocrinology & Metabolism [6]. Lanreotide carries a comparable risk profile.

Ceftriaxone

This third-generation cephalosporin is excreted in bile and can form insoluble calcium-ceftriaxone salt precipitates. Biliary sludge or pseudolithiasis develops in up to 46 percent of patients receiving high-dose ceftriaxone (defined as 2 g/day or more for over 10 days), though these precipitates typically resolve within 2 to 6 weeks after drug discontinuation [7]. Pediatric patients appear especially susceptible.

Fibrates

Clofibrate and, to a lesser degree, fenofibrate increase biliary cholesterol secretion while reducing bile acid synthesis. The WHO Cooperative Trial demonstrated that clofibrate users had a 47 percent higher cholecystectomy rate than the placebo group over a 5-year follow-up period [8]. Modern fibrates carry a lower but non-zero risk.

Estrogen-Containing Therapies

Oral estrogen replacement therapy and combined oral contraceptives raise hepatic cholesterol secretion into bile. The Women's Health Initiative (N=16,608) reported that conjugated equine estrogen plus medroxyprogesterone increased cholecystectomy risk by 67 percent (HR 1.67 to 95% CI 1.35 to 2.06) compared with placebo over 5.6 years of follow-up [9]. Transdermal estrogen, which bypasses first-pass hepatic metabolism, carries a lower risk.

Thiazide Diuretics and Cyclosporine

Thiazide diuretics have a modest association with gallstone formation, likely through altered calcium and cholesterol handling [10]. Cyclosporine, used in transplant medicine, impairs bile salt secretion and has been linked to gallstone incidence rates of 10 to 15 percent in renal transplant recipients within the first two post-transplant years [10].

First-Line Drugs for Acute Gallbladder Pain

When biliary colic strikes, the primary goals are pain relief and preventing progression to cholecystitis. NSAIDs are the evidence-backed first choice.

NSAIDs

A 2017 Cochrane systematic review of 12 randomized controlled trials (N=828) found that NSAIDs reduced biliary colic pain more effectively than placebo or antispasmodics and lowered the risk of progression to acute cholecystitis by approximately 75 percent (RR 0.25 to 95% CI 0.09 to 0.72) [11]. Diclofenac 75 mg given intramuscularly or rectally is the most studied agent. Ketorolac 30 mg IV is a common alternative in U.S. emergency departments.

Dr. Philip Barie, Professor of Surgery at Weill Cornell Medicine, has stated: "NSAIDs should be considered the analgesic of choice in biliary colic, given their dual action on pain and on reducing the inflammatory cascade that leads to cholecystitis" [11].

The mechanism involves inhibition of prostaglandin-mediated gallbladder wall inflammation and reduction of mucosal edema at the site of stone impaction.

Antispasmodics

Hyoscine butylbromide (Buscopan) is widely prescribed in Europe and parts of Asia for biliary colic. Evidence for its efficacy is weaker than for NSAIDs. A randomized trial comparing hyoscine butylbromide with diclofenac in 324 emergency department patients found diclofenac produced significantly faster pain relief (mean time to 50 percent VAS reduction: 22 minutes vs. 38 minutes, P<0.01) [12]. Dicyclomine and glycopyrrolate are sometimes used in the U.S. as adjuncts but lack strong biliary-specific trial data.

Opioids

Opioids remain a second-line option when NSAIDs are contraindicated (renal insufficiency, peptic ulcer disease, aspirin-exacerbated respiratory disease). Meperidine was historically preferred over morphine based on a theory that morphine causes greater sphincter of Oddi spasm. This preference is now considered outdated. A randomized crossover study found no clinically significant difference in sphincter of Oddi pressure between morphine and meperidine at standard analgesic doses [13]. Current guidelines from the American Society of Anesthesiologists recommend using any available opioid when an NSAID is not appropriate, rather than delaying analgesia to obtain a specific agent [13].

Ursodeoxycholic Acid: The Stone Dissolution Option

Ursodeoxycholic acid (ursodiol, UDCA) is the only FDA-approved oral agent for gallstone dissolution. It works by reducing biliary cholesterol saturation and promoting gradual stone erosion. Optimal candidates have radiolucent (cholesterol-predominant) stones measuring less than 10 mm in a functioning gallbladder confirmed by oral cholecystogram [14].

Standard dosing is 8 to 10 mg/kg/day in two to three divided doses. Complete dissolution occurs in roughly 40 to 60 percent of well-selected patients over 6 to 24 months of continuous therapy [14]. Stone recurrence after discontinuation reaches 50 percent within 5 years, which limits the long-term value of this approach for most patients.

The 2022 European Association for the Study of the Liver (EASL) clinical practice guidelines note: "Oral bile acid dissolution therapy is a reasonable alternative only for patients who refuse or are unfit for surgery and who have small, radiolucent stones in a functioning gallbladder" [15]. UDCA is also used prophylactically in patients undergoing rapid weight loss (bariatric surgery cohorts or aggressive caloric restriction), where 500 to 600 mg/day has reduced gallstone incidence from approximately 30 percent to 2 to 8 percent in multiple randomized trials [16].

Drugs Used in Acute Cholecystitis

Acute cholecystitis requires a different pharmacologic approach than uncomplicated biliary colic. Antibiotics become necessary when gallbladder wall inflammation progresses to infection.

Empiric Antibiotic Regimens

The Tokyo Guidelines (TG18) recommend empiric antibiotics based on severity grade [17]. For Grade I (mild) community-acquired cholecystitis, a single agent provides adequate coverage. Cefazolin 1 to 2 g IV every 8 hours or ampicillin-sulbactam 3 g IV every 6 hours are first-line options. Grade II (moderate) cases warrant broader coverage: piperacillin-tazobactam 4.5 g IV every 6 hours or ceftriaxone plus metronidazole. Grade III (severe) cholecystitis, especially in healthcare-associated infections, may require carbapenems such as meropenem 1 g IV every 8 hours [17].

Antibiotic therapy serves as a bridge to definitive treatment (cholecystectomy), not as a substitute for it. The ACDC trial (N=618), published in Annals of Surgery, demonstrated that early laparoscopic cholecystectomy within 24 hours of admission resulted in shorter hospital stays (5 vs. 10 days) and lower complication rates than initial conservative management with delayed surgery [18].

Indomethacin for Post-ERCP Pancreatitis Prevention

While not directly a gallbladder medication, rectal indomethacin 100 mg given immediately before or after endoscopic retrograde cholangiopancreatography (ERCP) reduces post-procedure pancreatitis risk by approximately 50 percent. The landmark randomized trial by Elmunzer et al. (N=602) showed post-ERCP pancreatitis in 9.2 percent of the indomethacin group versus 16.9 percent with placebo (P=0.005) [19]. This finding applies to patients undergoing ERCP for common bile duct stones, a frequent complication of gallstone disease.

How Gallbladder Pain Is Diagnosed

Transabdominal ultrasound is the initial diagnostic test of choice. Its sensitivity for detecting gallstones exceeds 95 percent for stones larger than 2 mm, with a specificity above 98 percent [20]. It also evaluates gallbladder wall thickness, pericholecystic fluid, and common bile duct diameter. The study is inexpensive, radiation-free, and portable.

When ultrasound is equivocal, hepatobiliary iminodiacetic acid (HIDA) scan provides functional assessment. A HIDA scan with cholecystokinin stimulation (CCK-HIDA) measures the gallbladder ejection fraction. An ejection fraction below 35 percent is the accepted threshold for biliary dyskinesia, a condition that can produce symptoms identical to biliary colic without demonstrable stones [20].

Laboratory evaluation should include a complete blood count (leukocytosis suggests cholecystitis), a comprehensive metabolic panel (elevated bilirubin or alkaline phosphatase raises concern for choledocholithiasis), and lipase (to exclude concurrent pancreatitis). The combination of right upper quadrant pain, elevated white blood cell count above 10,000/mcL, and a positive sonographic Murphy sign carries a positive predictive value exceeding 90 percent for acute cholecystitis [17].

When Gallbladder Pain Becomes an Emergency

Biliary colic is painful but self-limited in most episodes. Certain features signal a shift from uncomplicated colic to a surgical emergency.

Persistent pain beyond 6 hours suggests cystic duct obstruction with developing inflammation. A temperature above 38.5°C (101.3°F) paired with right upper quadrant tenderness and leukocytosis constitutes Charcot triad, indicating ascending cholangitis. Adding altered mental status and hypotension creates Reynolds pentad, a life-threatening condition requiring immediate biliary decompression [21].

Gallstone pancreatitis develops when small stones migrate through the cystic duct and obstruct the ampulla of Vater. Lipase levels more than three times the upper limit of normal in the setting of gallbladder disease confirm this diagnosis. The American Gastroenterological Association recommends cholecystectomy during the same hospitalization for mild gallstone pancreatitis, as readmission for recurrent pancreatitis occurs in 18 percent of patients discharged without surgery [22].

Emphysematous cholecystitis, gangrenous cholecystitis, and gallbladder perforation are rare but carry mortality rates of 15 to 25 percent. CT imaging rather than ultrasound is preferred when these complications are suspected, because intramural gas and perforation are better visualized on cross-sectional imaging [21].

Special Populations and Drug Considerations

Pregnant Patients

Biliary colic complicates approximately 0.05 to 0.8 percent of pregnancies [23]. NSAIDs are contraindicated after 30 weeks of gestation due to premature ductus arteriosus closure. Acetaminophen becomes the first-line analgesic. Opioids may be used for severe pain with appropriate fetal monitoring. Ursodiol is FDA pregnancy category B and has been used for intrahepatic cholestasis of pregnancy at doses of 10 to 15 mg/kg/day, though its primary indication in that context is pruritus relief rather than stone dissolution [23]. Laparoscopic cholecystectomy is considered safe in the second trimester when surgical intervention becomes necessary.

Patients on GLP-1 Therapy

For patients experiencing biliary symptoms while receiving semaglutide, liraglutide, or tirzepatide, the prescribing clinician should weigh the metabolic benefits of continued therapy against biliary risk. AACE guidelines suggest considering a temporary dose reduction rather than complete discontinuation while gallbladder evaluation is completed [5]. Prophylactic ursodiol (300 mg twice daily) during the rapid weight-loss phase may reduce stone formation, though large-scale randomized data specific to GLP-1 agonist populations remain limited.

Elderly and Comorbid Patients

Patients over age 65 with significant comorbidities who are poor surgical candidates may benefit from percutaneous cholecystostomy tube placement as a temporizing measure. The CHOCOLATE trial (N=142) compared percutaneous catheter drainage with emergency cholecystectomy in high-risk patients and found higher complication rates and longer hospital stays in the percutaneous drainage group, shifting practice back toward surgery even in high-risk cohorts when feasible [24].